PLUS1
0.65
0.035 (5.69%)
0.035 (5.69%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Outlook Therapeutics Inc | OTLK | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.0251 | 4.25% | 0.615 | 0.59 | 0.63 | 0.61 | 0.5899 | 19:29:57 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.60 | 0.65 | 0.05 | 7.69% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,425 | 502,803 | $ 0.6051228 | $ 304,258 | 449,136 | 0.4011 - 4.6557 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:29:57 | formt | 1,000 | $ 0.65 | USD |
Outlook Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 50.74M | 82.51M | $ -30.09M | -2.42 | - | 74.32M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 7.00 | 9.90% |
Outlook Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/08/2020 | 17:05 | Edgar (US Regulatory) | Securities Registration Statement (s-1) |
| 4/02/2020 | 17:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 3/24/2020 | 17:23 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 3/24/2020 | 16:18 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 3/23/2020 | 17:36 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 3/20/2020 | 17:56 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 3/20/2020 | 17:55 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OTLK Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.5885 | 0.63 | 0.5599 | 0.5757753 | 188,302 | 0.0265 | 4.5% |
| 1 Month | 0.64 | 0.68 | 0.499 | 0.5750569 | 353,572 | -0.025 | -3.91% |
| 3 Months | 0.8783 | 1.12 | 0.499 | 0.8194219 | 468,128 | -0.2633 | -29.98% |
| 6 Months | 1.36 | 1.74 | 0.4011 | 0.9344866 | 650,323 | -0.745 | -54.78% |
| 1 Year | 4.56 | 4.6557 | 0.4011 | 2.03 | 1,736,934 | -3.95 | -86.51% |
| 3 Years | 5.60 | 20.00 | 0.4011 | 2.26 | 1,358,306 | -4.99 | -89.02% |
| 5 Years | 5.60 | 20.00 | 0.4011 | 2.26 | 1,358,306 | -4.99 | -89.02% |
Outlook Therapeutics Description
| Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. |
